If you are a member of the media and have questions about Bayer in Canada, please contact Marija Mandic, Director of Communications, at email@example.com, or 416-240-5376, or Emily Hanft, Senior Business Communications Partner, at firstname.lastname@example.org, or 416-240-5466.
April 24, 2014Quebecers suffering from wet Age-Related Macular Degeneration first with government coverage
April 24, 2014Québec First Province to List Adempas® for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
April 22, 2014Two Green Thumbs Up for Bayer! Bayer named one of Canada’s Greenest Employers for the sixth consecutive year
April 17, 2014When Living With Hemophilia, It’s All About Attitude
March 10, 2014Adempas® now approved for second rare heart and lung disease, offering a new treatment option to improve patient care
February 26, 2014No Need to Fret, Ferret Friends! Advantage Multi® 9 is the First and Only Approved Therapy to Prevent Heartworm Disease...
February 5, 2014New Study: 4 in 10 Canadians Admit They Or A Partner Have Had A ‘Pregnancy Scare’
January 13, 2014Bayer HealthCare Announces Baycox® 5% (toltrazuril) Oral Suspension Approved for Sheep in Canada
December 18, 2013Bayer HealthCare to Join Not-For-Profit Structural Genomics Consortium to Accelerate Research in Epigenetics
November 27, 2013Bayer Is in Seventh Heaven!
November 14, 2013Real-World Data Confirm Clinical Value of Bayer’s Novel Oral Anticoagulant Xarelto in Protecting Patients Against Blood Clots
November 12, 2013Bayer receives approval for Eylea® as new drug to treat wet Age-Related Macular Degeneration Patients in Canada
October 21, 2013Bayer Comes Out on Top Once Again!
October 17, 2013Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
September 26, 2013Bayer Recognized as a Top Place to Work for Canada’s Young People for a Third Time
September 23, 2013Bayer receives approval for Adempas® as first drug to treat rare heart and lung disease
September 16, 2013150 Years of Bayer: pop song for a good cause
July 25, 2013New England Journal of Medicine Publishes Results of Two Pivotal Phase III Studies of Bayer’s Riociguat
July 18, 2013Bayer Announces that New England Journal of Medicine Publishes Results from Phase III ALSYMPCA Study of Radium 223 Dichloride
May 7, 2013Saluting Canadian innovators who embody Bayer’s philosophy: Science for a Better Life